MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
OptimizeRx Corporation Income Statement 2011-2026 | OPRX
Annual Income Statement OptimizeRx Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
177 M | 237 M | 774 M | 669 M | 151 M | 119 M | 41.5 M | 23.8 M | 26.5 M | 23.7 M | 26.9 M | 14.9 M | 11.1 M |
Shares |
17.1 M | 17.8 M | 17.2 M | 14.8 M | 13.4 M | 10.8 M | 9.82 M | 9.9 M | 8.19 M | 7.46 M | 4.8 M | 4.74 M | 4.64 M |
Historical Prices |
10.3 | 13.3 | 44.9 | 45.1 | 11.1 | 11.2 | 4.11 | 2.31 | 3.24 | 3.18 | 5.61 | 3.15 | 2.4 |
Net Income |
-17.6 M | -11.4 M | 378 K | -2.21 M | -3.14 M | 226 K | -2.1 M | -1.54 M | -595 K | -1.03 M | 216 K | -364 K | -2.12 M |
Revenue |
71.5 M | 62.5 M | 61.3 M | 43.3 M | 24.6 M | 21.2 M | 12.1 M | 7.75 M | 7.22 M | 6.5 M | 4.96 M | 2.05 M | 1.11 M |
Cost of Revenue |
28.6 M | 23.5 M | 25.7 M | 19.2 M | 9.16 M | 9 M | - | - | - | - | - | - | - |
Gross Profit |
42.9 M | 39 M | 35.6 M | 24.1 M | 15.4 M | 12.2 M | 5.95 M | 4.34 M | 3.6 M | 3.28 M | 3.19 M | 2.05 M | 1.11 M |
Operating Income |
-26.4 M | -12.3 M | 361 K | -2.14 M | -3.69 M | 180 K | -2.13 M | -1.58 M | -597 K | -1.03 M | -268 K | -455 K | -1.45 M |
Interest Expense |
1.45 M | 852 K | 17 K | -71.8 K | -347 K | 46.2 K | - | - | - | - | - | 100 | -959 K |
EBITDA |
-24 M | -10.3 M | 2.33 M | -59.4 K | -1.61 M | 1.1 M | -1.81 M | -1.3 M | -263 K | -362 K | 410 K | -177 K | -1.31 M |
Operating Expenses |
69.3 M | 51.3 M | 35.3 M | 26.2 M | 18.3 M | 11.4 M | 8.08 M | 5.87 M | 4.2 M | 3.91 M | 2.97 M | 2.41 M | 2.57 M |
General and Administrative Expenses |
776 K | 744 K | 27.7 M | 21 M | 13.5 M | 9.99 M | 6.54 M | 4.94 M | 3.27 M | 3.37 M | 2.73 M | 2.17 M | 2.02 M |
All numbers in USD currency
Quarterly Income Statement OptimizeRx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.6 M | 18.5 M | 18.5 M | 18.5 M | 18.3 M | 18.3 M | 18.2 M | 18.2 M | 16.6 M | 17 M | 17.1 M | 18.3 M | 18 M | 18.1 M | 17.9 M | 17.9 M | 17.6 M | 17.3 M | 16.1 M | 15.2 M | 14.9 M | 14.7 M | 14.6 M | 14.6 M | 14.1 M | 12.7 M | 12.1 M | 12 M | 11.8 M | 11 M | 9.79 M | 9.77 M | 9.75 M | 9.86 M | 29.7 M | 29.7 M | 29.4 M | 29.1 M | 29 M | 29 M | 23.3 M | 22.9 M | 22.9 M | 22.9 M | 23.4 M | 23.2 M | 16.7 M | 14.8 M | 14.2 M | 33.6 M | 14.2 M | - | 14.2 M | 14.2 M | - | - | - | - | - |
Net Income |
779 K | 1.53 M | -2.2 M | - | -9.12 M | -4.01 M | -6.9 M | - | -2.86 M | -4.16 M | -6.4 M | - | -3.47 M | -3.88 M | -3.76 M | - | 39.9 K | 352 K | -637 K | - | -283 K | -1.08 M | -2.2 M | - | -1.57 M | 407 K | 6.53 K | - | 245 K | 281 K | -189 K | - | -623 K | -362 K | -883 K | - | -243 K | -592 K | -352 K | - | 87.9 K | -157 K | -111 K | - | -295 K | -199 K | -762 K | - | -412 K | -248 K | -224 K | - | -483 K | -377 K | -301 K | - | -2.03 M | -433 K | -380 K |
Revenue |
26.1 M | 29.2 M | 21.9 M | - | 21.3 M | 18.8 M | 19.7 M | - | 16.3 M | 13.8 M | 13 M | - | 15.1 M | 14 M | 13.7 M | - | 16.1 M | 13.6 M | 11.2 M | - | 10.5 M | 8.78 M | 7.58 M | - | 5 M | 7.01 M | 5.21 M | - | 5.42 M | 5.1 M | 2.78 M | - | 3.1 M | 2.87 M | 1.4 M | - | 1.79 M | 1.91 M | 1.76 M | - | 2.01 M | 1.71 M | 1.49 M | - | 1.82 M | 1.43 M | 1.29 M | - | 1.37 M | 1.1 M | 669 K | - | 77 | 146 | 185 | - | 206 | 395 | 440 |
Cost of Revenue |
8.55 M | 10.6 M | 8.58 M | - | 7.86 M | 7.11 M | 7.49 M | - | 6.53 M | 5.99 M | 5.57 M | - | 5.66 M | 4.99 M | 5.63 M | - | 7.05 M | 5.58 M | 5.1 M | - | 4.5 M | 3.64 M | 3.24 M | - | 1.98 M | 2.69 M | 1.58 M | - | 2.27 M | 2.24 M | 2.01 M | - | - | - | 1.38 M | - | - | - | 893 K | - | - | - | - | - | 859 K | - | - | - | 529 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
17.5 M | 18.6 M | 13.3 M | - | 13.4 M | 11.7 M | 12.2 M | - | 9.8 M | 7.82 M | 7.43 M | - | 9.42 M | 8.99 M | 8.1 M | - | 9.08 M | 8.04 M | 6.12 M | - | 6.01 M | 5.14 M | 4.34 M | - | 3.02 M | 4.32 M | 3.63 M | - | 3.15 M | 2.86 M | 2.1 M | - | 1.4 M | 1.26 M | 770 K | - | 1.06 M | 990 K | 867 K | - | 963 K | 823 K | 731 K | - | 861 K | 697 K | 728 K | - | 844 K | 1.04 M | 653 K | - | - | - | - | - | - | - | - |
Operating Income |
2.05 M | 3.19 M | -2.11 M | - | -8.56 M | -3.75 M | -5.03 M | - | -3.55 M | -4.85 M | -7.06 M | - | -3.76 M | -3.91 M | -3.76 M | - | 38.2 K | 340 K | -638 K | - | -177 K | -1.06 M | -2.26 M | - | -1.99 M | 480 K | 132 K | - | 223 K | 274 K | -191 K | - | -630 K | -371 K | -890 K | - | -249 K | -603 K | -362 K | - | 87.6 K | -158 K | -111 K | - | -295 K | -200 K | -762 K | - | -142 K | 354 K | 99.8 K | - | -106 K | -76.2 K | -301 K | - | 13.5 M | -420 K | -240 K |
Interest Expense |
- | - | - | - | - | - | 1.55 M | - | 688 K | 720 K | 665 K | - | 290 K | 23.8 K | 3 | - | 1.7 K | 12 K | 931 | - | -106 K | -21.7 K | 55.3 K | - | 416 K | -73.4 K | -126 K | - | - | - | - | - | - | - | - | - | 163 | 163 | 163 | - | - | - | - | - | - | - | - | - | - | - | - | - | -100 | - | - | - | -679 K | -140 K | -140 K |
EBITDA |
3.13 M | 4.26 M | -1.02 M | - | -7.47 M | -2.68 M | -3.96 M | - | -3.09 M | -4.38 M | -6.6 M | - | -3.24 M | -3.33 M | -3.29 M | - | 1.62 M | 1.39 M | -638 K | - | -177 K | -1.06 M | -1.74 M | - | -1.24 M | 906 K | 322 K | - | 387 K | 383 K | -137 K | - | -417 K | -229 K | -819 K | - | -95.2 K | -501 K | -312 K | - | 330 K | 1.81 K | -31.8 K | - | -112 K | -84 K | -703 K | - | -93.4 K | 402 K | 148 K | - | -59.4 K | -28.9 K | -255 K | - | 13.5 M | -390 K | -210 K |
Operating Expenses |
15.5 M | 15.4 M | 15.5 M | - | 22 M | 15.5 M | 17.2 M | - | 13.4 M | 12.7 M | 14.5 M | - | 13.2 M | 12.9 M | 11.9 M | - | 9.04 M | 7.7 M | 6.76 M | - | 6.19 M | 6.2 M | 6.6 M | - | 5.01 M | 3.84 M | 3.49 M | - | 2.92 M | 2.59 M | 2.3 M | - | 2.03 M | 1.63 M | 1.66 M | - | 1.31 M | 1.59 M | 1.23 M | - | 875 K | 981 K | 843 K | - | 1.16 M | 897 K | 1.49 M | - | 1.08 M | 750 K | 553 K | - | 559 K | 592 K | 630 K | - | 601 K | 621 K | 634 K |
General and Administrative Expenses |
14.4 M | 14.4 M | 14.4 M | - | 13.4 M | 14.4 M | 16.2 M | - | 12.9 M | 12.2 M | 14 M | - | 12.7 M | 12.3 M | 11.4 M | - | 3.41 M | 2.9 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.3 K | - | 94.8 K | 56.5 K | 219 K | - | 63.2 K | 57.1 K | 77 K | - | 133 K | 101 K | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company OptimizeRx Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
American Well Corporation
AMWL
|
$ 5.55 | -1.42 % | $ 89.1 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Schrödinger
SDGR
|
$ 11.52 | 1.05 % | $ 846 M | USA |
 |
Phreesia
PHR
|
$ 11.52 | 2.49 % | $ 629 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Teladoc Health
TDOC
|
$ 5.52 | -0.9 % | $ 973 M | USA |
 |
Evolent Health
EVH
|
$ 2.3 | 1.55 % | $ 216 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
10x Genomics
TXG
|
$ 20.97 | 0.29 % | $ 2.46 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.06 | -0.24 % | $ 795 M | USA |
 |
SCWorx Corp.
WORX
|
$ 0.14 | 7.38 % | $ 204 K | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
HealthStream
HSTM
|
$ 21.24 | 0.05 % | $ 645 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.78 | -1.11 % | $ 9.27 M |  China |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.09 | -0.91 % | $ 76.2 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
HealthEquity
HQY
|
$ 83.31 | 1.01 % | $ 7.18 B | USA |
 |
Omnicell
OMCL
|
$ 35.35 | 1.17 % | $ 1.63 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Progyny
PGNY
|
$ 17.91 | 0.9 % | $ 1.54 B | USA |
 |
So-Young International
SY
|
$ 2.88 | -9.87 % | $ 229 M | China |
 |
Veeva Systems
VEEV
|
$ 180.16 | 1.17 % | $ 29.5 B | USA |